Viemed to Centralize Market for Common Shares on NASDAQ Through Voluntary Delisting from TSX
07 Dezembro 2023 - 11:00AM
Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD and
TSX:VMD.TO), a national leader in respiratory care and
technology-enabled home medical equipment services, announced that
it has applied and received approval from the Toronto Stock
Exchange (“TSX”) for the voluntary delisting of its common shares
(each a “Common Share”) from the TSX. The delisting from TSX will
not affect the Company's listing on the NASDAQ Capital Market
("NASDAQ").
“The Company is taking strategic action to
enhance market efficiency and optimize our administrative processes
by consolidating trading volumes on NASDAQ, as the majority of both
outstanding shares and trading volume is currently concentrated in
the United States. The delisting from TSX will create a singular
focal point and central marketplace for the Company’s common
shares, contributing to increased long-term liquidity on NASDAQ and
increased shareholder value.” said Viemed Chief Operating Officer,
Todd Zehnder.
The Common Shares will be delisted from TSX
effective as of close of markets on December 21, 2023. In
accordance with the TSX Company Manual, TSX does not require
shareholder approval of the voluntary delisting of the Common
Shares from TSX, as an acceptable alternative market will exist for
the Common Shares on the date of delisting. The Common Shares will
continue to trade on NASDAQ under the symbol “VMD".
Following delisting from TSX, Viemed's
shareholders can trade their Common Shares through their brokers on
NASDAQ. As most brokers in Canada, including many discount and
online brokers, have the ability to buy and sell securities listed
on NASDAQ, Viemed’s NASDAQ listing will continue to provide
shareholders with the same accessibility to trade the Common
Shares. Shareholders holding their shares in Canadian brokerage
accounts should contact their brokers to confirm how to trade
Viemed’s shares on NASDAQ.
ABOUT VIEMED HEALTHCARE, INC.
Viemed is a provider of in-home medical
equipment and post-acute respiratory healthcare services in the
United States. Viemed’s service offerings are focused on effective
in-home treatment with clinical practitioners providing therapy and
counseling to patients in their homes using cutting-edge
technology. Visit our website at www.viemed.com.
For further information, please contact:
Glen AkselrodBristol
Capital905-326-1888glen@bristolir.com
Todd ZehnderChief Operating OfficerViemed
Healthcare,
Inc.337-504-3802investorinfo@viemed.comForward-Looking
Statements
Certain statements contained in this press
release may constitute “forward-looking statements” within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995 or “forward-looking information” as such term is defined in
applicable Canadian securities legislation (collectively,
“forward-looking statements”). Often, but not always,
forward-looking statements can be identified by the use of words
such as “plans”, “expects”, “is expected”, “budget”, “potential”,
“scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”,
“believes”, or “projects”, or the negatives thereof or variations
of such words and phrases or statements that certain actions,
events or results “will”, “should”, “may”, “could”, “would”,
“might” or “will be taken”, “occur” or “be achieved” or the
negative of these terms or comparable terminology, all statements
other than statements of historical fact, including those that
express, or involve discussions as to, expectations, beliefs,
plans, objectives, assumptions or future events or performance,
including the anticipated results of delisting and consolidated
trading on Nasdaq. Such statements reflect the Company's current
views and intentions with respect to future events, and current
information available to the Company, and are subject to certain
risks, uncertainties and assumptions. Many factors could cause the
actual results, performance or achievements that may be expressed
or implied by such forward-looking statements to vary from those
described herein should one or more of these risks or uncertainties
materialize. These factors include, without limitation: the general
business, market and economic conditions in the regions in which
the Company operates; the impact of the COVID-19 pandemic and the
actions taken by governmental authorities, individuals and
companies in response to the pandemic on our business, financial
condition and results of operations, including on the Company's
patient base, revenues, employees, and equipment and supplies;
significant capital requirements and operating risks that the
Company may be subject to; the ability of the Company to implement
business strategies and pursue business opportunities; volatility
in the market price of the Company's common shares; the Company’s
novel business model; the state of the capital markets; the
availability of funds and resources to pursue operations;
reductions in reimbursement rates and audits of reimbursement
claims by various governmental and private payor entities;
dependence on few payors; possible new drug discoveries; dependence
on key suppliers; granting of permits and licenses in a highly
regulated business; competition; disruptions in or attacks
(including cyber-attacks) on the Company's information technology,
internet, network access or other voice or data communications
systems or services; the evolution of various types of fraud or
other criminal behavior to which the Company is exposed; difficulty
integrating newly acquired businesses; the impact of new and
changes to, or application of, current laws and regulations; the
overall difficult litigation and regulatory environment; increased
competition; increased funding costs and market volatility due to
market illiquidity and competition for funding; critical accounting
estimates and changes to accounting standards, policies, and
methods used by the Company; the Company’s status as an emerging
growth company and a smaller reporting company; and the occurrence
of natural and unnatural catastrophic events or health epidemics or
concerns, such as the COVID-19 pandemic, and claims resulting from
such events or concerns; as well as those risk factors discussed or
referred to in the Company’s disclosure documents, including the
Company’s most recent Annual Report on Form 10-K and Quarterly
Report on Form 10-Q, filed with the U.S. Securities and Exchange
Commission (the “SEC”) available on the SEC’s website at
www.sec.gov, and with the securities regulatory authorities in
certain provinces of Canada available at www.sedar.com. Should any
factor affect the Company in an unexpected manner, or should
assumptions underlying the forward-looking statements prove
incorrect, the actual results or events may differ materially from
the results or events predicted. Any such forward-looking
statements are expressly qualified in their entirety by this
cautionary statement. Moreover, the Company does not assume
responsibility for the accuracy or completeness of such
forward-looking statements. The forward-looking statements included
in this press release are made as of the date of this press release
and the Company undertakes no obligation to publicly update or
revise any forward-looking statements, other than as required by
applicable law.
VieMed Healthcare (NASDAQ:VMD)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
VieMed Healthcare (NASDAQ:VMD)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024